The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient Therapeutics Ltd (ASX:PTX) at its annual meeting in Paris, which runs from May 31 to June 3.
Researchers will present new pre-clinical data on Prescient’s next-generation modular, controllable CAR platform, OmniCAR, and its cell therapy enhancement platform, CellPryme.
Both abstracts will also be published in the next issue of Cytotherapy, the official journal of the ISCT.
Shared vision for cell and gene therapy
The ISCT brings together clinicians, regulators, researchers, technologists and industry partners with a shared vision to translate cell and gene therapy into safe and effective therapies to improve patients' lives worldwide.
The ISCT is the global leader focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics, thereby advancing scientific research into innovative treatments for patients.
The annual conference attracts more than 2,700 cell and gene therapy experts from 60 countries.
Showcasing opportunity
Prescient’s senior vice president of scientific affairs Dr Rebecca Lim said: “Prescient has made significant progress with the development of its cell therapy platforms, OmniCAR and CellPryme, which have the potential to advance the utility and utilisation of cell therapies.
“The ISCT meeting is a wonderful opportunity for us to showcase our OmniCAR and CellPryme data to an expert cell therapy audience of researchers, clinicians and pharmaceutical industry delegates.”
Prescient CEO and managing director Steven Yatomi-Clarke added: “To have not one but two abstracts accepted by this prestigious conference is testament to the quality and novelty of our science, and also exemplifies how both the OmniCAR and CellPryme platforms are positioned at the forefront of cell therapy utility and innovation.”
About OmniCAR
OmniCAR is a universal immune receptor platform to control T-cell activity and enable multi-antigen targeting with a single-cell product.
OmniCAR’s modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells.
About CellPryme
Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. It’s a 24-hour, non-disruptive process that takes place during cell manufacturing.
CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment.